Hilden, Germany, and Germantown, Maryland, April 19, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat-Dxâ in Europe, providing a one-step, fully integrated molecular analysis of common syndromes as tested for in syndromes in infections, oncology and other diseases. The launch follows the closing of the acquisition of Stat-Dx... Read more
Germantown, Maryland, and Hilden, Germany, April 12, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today launched two novel liquid biopsy panels to evaluate circulating tumor cells (CTCs) in the growing field of research into molecular mechanisms in prostate and lung cancers. The AdnaTest ProstateCancerPanel AR-V7 Kit and AdnaTest LungCancer Kit will be... Read more
HILDEN, Deutschland und AARHUS, Dänemark, February 2, 2016 /PRNewswire/ — Zentren und Wissenschaftler der FDA erhalten Zugang zu QIAGENs umfangreichen Lösungen für Anwendungen in der mikrobiellen und metagenomischen Analyse sowie anderen Bereichen QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass das Unternehmen neue Partnerschaften eingegangen ist, um das Profil seiner... Read more
VENLO, Niederlande, February 2, 2016 /PRNewswire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse der operativen Tätigkeit für das vierte Quartal und für das Gesamtjahr 2015 bekannt. Das Unternehmen hat auf Basis konstanter Wechselkurse (CER) den bereinigten Konzernumsatz und Gewinn gesteigert. Gleichzeitig hat QIAGEN Ziele für die Beschleunigung von Wachstum... Read more
HANOI, Vietnam, June 6 /PRNewswire-FirstCall/ -- QIAGEN was featured this week for its efforts to eliminate cervical cancer at the 14th annual Global Summit of Women in Hanoi, Vietnam. CEO Peer Schatz came to this prominent international platform to issue a call to other leaders in business, NGOs and governments to join him and campaign... Read more
HILDEN, Germany and AARHUS, Denmark, February 2, 2016 /PRNewswire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced new partnerships to enhance the profile and expand the use of its market leading bioinformatics solutions for microbiome, metagenomics and other applications. QIAGEN Bioinformatics signed an agreement with genomics big data company CosmosID, Inc. to... Read more
VENLO, The Netherlands, February 2, 2016 /PRNewswire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2015, delivering higher adjusted net sales and earnings at constant exchange rates (CER) while setting goals for accelerating growth and further innovation in 2016. “QIAGEN made significant progress in... Read more
Germantown, Maryland, and Hilden, Germany, March 14, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that its QuantiFERON-TB® Gold Plus (QFT-Plus), the gold standard in accurate, cost-effective testing for latent tuberculosis (TB) infection, has been endorsed for immigration medical screening by the International Panel Physicians Association (IPPA). IPPA is a not-for-profit... Read more
Hilden, Germany, and San Carlos, CA, March 12, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. (NASDAQ: NTRA), a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today... Read more
MAR 12 2018 Hilden, Germany, and San Carlos, CA, March 12, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. (NASDAQ: NTRA), a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor... Read more